{"id":802136,"date":"2026-04-14T14:13:01","date_gmt":"2026-04-14T14:13:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=802136"},"modified":"2026-04-14T14:13:01","modified_gmt":"2026-04-14T14:13:01","slug":"type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences_802136.html","title":{"rendered":"Type 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind Biosciences"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1776178206.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Type 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind Biosciences\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1776178206.jpg\" alt=\"Type 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind Biosciences\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Type 2 Diabetes \u2013 Pipeline Insight, 2026<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">There are 75+ key companies, such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others, developing therapies for Type 2 Diabetes, with Eli Lilly and Company having its Type 2 Diabetes drug candidate in the most advanced Phase III stage.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Type 2 Diabetes &ndash; Pipeline Insight, 2026<\/strong>&#8221; report provides comprehensive insights about 75+ companies developing 80+ pipeline drugs in the Type 2 Diabetes pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><em>Explore the latest breakthroughs in the Type 2 Diabetes treatment landscape. Learn more about the evolving Type 2 Diabetes pipeline today @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Type 2 Diabetes Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>On March 05, 2026<\/strong>, <strong>Eli Lilly and Company initiated a Phase 3 study<\/strong> to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control.<\/p>\n<\/li>\n<li>\n<p><strong>On March 03, 2026, AstraZeneca announced a Phase II study,<\/strong> a randomized, parallel group, double-blinded, placebo-controlled, multicenter trial, to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and Type 2 Diabetes on stable GLP-1 RA therapy.<\/p>\n<\/li>\n<li>\n<p>DelveInsight&#8217;s Type 2 Diabetes Pipeline Insight report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment.<\/p>\n<\/li>\n<li>\n<p>The leading Type 2 Diabetes companies include <strong>Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others.<\/strong><\/p>\n<\/li>\n<li>\n<p>Promising Type 2 Diabetes therapies include <strong>Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine\/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Download for updates and the latest revolution in Type 2 Diabetes care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Type 2 Diabetes Clinical Trials Assessment<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Type 2 Diabetes Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>XW014:<\/strong> Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Type 2 Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, mimicking the action of the GLP-1 hormone released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination use with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.<\/p>\n<\/li>\n<li>\n<p><strong>KN056:<\/strong> Suzhou Alphamab Co., Ltd. KN056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. KN056 targets the GLP-1 receptor &mdash; a key regulator of glucose metabolism that stimulates insulin secretion, inhibits glucagon release, and promotes satiety. By modulating the GLP-1 receptor, KN056 aims to improve glycemic control in patients with Type 2 Diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>For more information on the Type 2 Diabetes Emerging Drugs Profile, download DelveInsight&#8217;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">comprehensive Type 2 Diabetes Pipeline Insight report<\/a>.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>The Type 2 Diabetes Pipeline Report Provides<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Detailed insights about companies developing therapies for Type 2 Diabetes, with aggregate therapies developed by each company.<\/p>\n<\/li>\n<li>\n<p>Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes treatment.<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company&ndash;company and company&ndash;academia), licensing agreements, and financing details for future advancement of the Type 2 Diabetes market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Learn more about Type 2 Diabetes drug opportunities in our comprehensive Type 2 Diabetes pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Type 2 Diabetes Unmet Needs<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Type 2 Diabetes Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">There are 75+ key companies, such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others, developing therapies for Type 2 Diabetes, with Eli Lilly and Company having its Type 2 Diabetes drug candidate in the most advanced Phase III stage.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Tropical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Type 2 Diabetes products have been categorized under various Molecule types such as:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Gene Therapy<\/p>\n<\/li>\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Recombinant protein<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=xpr\">Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives<\/a><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Type 2 Diabetes Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Coverage: Global<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes companies: Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Therapies: Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine\/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes: Overview<\/p>\n<\/li>\n<li>\n<p>Pipeline Therapeutics<\/p>\n<\/li>\n<li>\n<p>Therapeutic Assessment<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes &ndash; DelveInsight&#8217;s Analytical Perspective<\/p>\n<\/li>\n<li>\n<p>Late Stage Products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid Stage Products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early Stage Products (Phase I)<\/p>\n<\/li>\n<li>\n<p>Preclinical and Discovery Stage Products<\/p>\n<\/li>\n<li>\n<p>Inactive Products<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Key Companies<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Key Products<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Market Drivers and Barriers<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Future Perspectives and Conclusion<\/p>\n<\/li>\n<li>\n<p>Type 2 Diabetes Analyst Views<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<\/ol>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Arpit Anand<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type 2 Diabetes \u2013 Pipeline Insight, 2026 There are 75+ key companies, such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences_802136.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-802136","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/802136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=802136"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/802136\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=802136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=802136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=802136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}